作者与单位 Authors & Affiliations
Yvonne A. Evrard1, Ting-Chia Chang2, Jasmine B'Lanton1, Gareth Bliss1, Alice Chen3, Li Chen2, Kevin Cooper1, Kristin Cox1, Natalie Czarra1, Isabella Czernia1, Biswajit Das2, Kelly Dougherty1, Aarin Dreyer1, Lindsay Dutko2, Katie Frey1, Marion Gibson1, Tara Grinnage-Pulley4, Shahanawaz Jiwani2, Poorva Juneja2, Keegan Kalmbach1, Tamikia Lamb1, Eva Loewenstein1, Candace Mallow1, Chelsea McGlynn1, Justine Mills1, Michael Mullendore1, Matthew Murphy1, Sandra Navas-Reyes1, Michelle Norris1, Jessica Park2, Kaci Paulus2, Kevin Plater1, Tia Shearer1, Jessica Steed1, Luke Stockwin1, Howard Stotler1, Ruth Thornton2, Cindy R. Timme1, Shannon Uzelac1, Dianne L. Newton1, Chris A. Karlovich2, Melinda G. Hollingshead4, James H. Doroshow3
1Frederick National Laboratory for Cancer Research, Frederick, MD,2Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD,3Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,4Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute-Frederick, Frederick, MD
摘要 Abstract
Head and neck (HN) cancers are a rare set of cancers defined by their anatomical point of origin including mouth, sinus, throat, or nose. Human papilloma virus (HPV) infection plays a pathogenic role in HN cancers resulting in distinct clinical and molecular characteristics from those that are HPV-. The National Cancer Institute's Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) has developed a national repository of patient-derived models (PDMs) comprised of patient-derived xenografts (PDXs), organoids (PDOrg), tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs). These models are clinically annotated with molecular information available in a public database for the extramural community. To date, 361 patient HN tumor specimens have been received from 351 unique patients across a range of histologies including lip/oral, pharyngeal, laryngeal, salivary and sinonasal with an overall PDX take rate of 48% (322 assessable specimens). The NCI PDMR currently has 200 public HN PDX, PDOrg, and PDC models from 124 unique patients. Thirty-three models (PDX, PDOrg, PDC) from 20 unique patients are positive for HPV16 or 18 (one double positive) as detected by PCR and one sinonasal PDOrg model is positive for HPV33 identified in NextGenSeq data. As has been reported in the clinical literature, TP53 and CDKN2A mutations are found predominantly in PDX models that are HPV- (84% and 65%, respectively) but not HPV+ (0%; 0%) and PIK3CA is more commonly mutated in HPV+ models (47% vs 25%). No significant difference in loss of heterozygosity is observed in the models. However, significant differences in chromosome arm copy number changes (copy gains in 7p, 11p and 12p and copy losses in 3p, 9p and 18q [P-value<0.05; Wilcoxon Rank-Sum test]) are observed in HPV- compared to HPV+ models. Gene set enrichment analysis (GSEA) suggest the E2F_TARGETS, G2M_CHECKPOINT, and DNA_REPAIR gene sets are significantly up-regulated in HPV+ while the APOPTOSIS gene set is significantly down-regulated using MSigDB Hallmark dataset (P-value<0.05). In all analyses, differences are consistent whether examining in vivo PDX models or in vitro PDC/PDOrg models indicating the fidelity of the models. These preclinical models recapitulate the molecular differences reported in HPV+ versus HPV- clinical cases providing an important tool for the development of novel therapeutics for HN cancers. Funded by NCI Contract No. HHSN261200800001E
利益披露 Disclosure
Y. A. Evrard, None..
T. Chang, None..
J. B'Lanton, None..
G. Bliss, None..
A. Chen, None..
L. Chen, None..
K. Cooper, None..
K. Cox, None..
N. Czarra, None..
I. Czernia, None..
B. Das, None..
K. Dougherty, None..
A. Dreyer, None..
L. Dutko, None..
K. Frey, None..
M. Gibson, None..
T. Grinnage-Pulley, None..
S. Jiwani, None..
P. Juneja, None..
K. Kalmbach, None..
T. Lamb, None..
E. Loewenstein, None..
C. Mallow, None..
C. McGlynn, None..
J. Mills, None..
M. Mullendore, None..
M. Murphy, None..
S. Navas-Reyes, None..
M. Norris, None..
J. Park, None..
K. Paulus, None..
K. Plater, None..
T. Shearer, None..
J. Steed, None..
L. Stockwin, None..
H. Stotler, None..
R. Thornton, None..
C. R. Timme, None..
S. Uzelac, None..
D. L. Newton, None..
C. A. Karlovich, None..
M. G. Hollingshead, None..
J. H. Doroshow, None.